Document Detail

Systemic treatment of severe acne with a retinoic acid derivative, isotretinoin.
MedLine Citation:
PMID:  6231496     Owner:  NLM     Status:  MEDLINE    
Twenty-eight patients with severe acne and one with hidradenitis suppurativa and acne were treated for 12 to 16 weeks with a new synthetic retinoid, isotretinoin (Roaccutane). The average dose was 0.56 mg/kg/day. Patients were seen weekly for four weeks and then fortnightly for the remaining treatment period, being evaluated both qualitatively and quantitatively. Twenty-five patients had an excellent response. Two to five months after the end of treatment no patient had relapsed. No patient withdrew because of side effects, but all suffered dry lips. This study confirms the potential of isotretinoin in the treatment of severe acne.
J M Wishart
Related Documents :
19925596 - Notalgia paresthesica successfully treated with narrow-band uvb: report of five cases.
21916766 - Evaluation of epidemiological, clinical, and pathological features of neuroaxonal dystr...
15943496 - Imiquimod: in superficial basal cell carcinoma.
6454596 - Ro 11-1430, a new retinoic acid derivative for the topical treatment of acne.
17283006 - Randomized, double-blind comparison of patient-controlled epidural infusion vs nurse-ad...
22322606 - Recanalization with wingspan stent for acute middle cerebral artery occlusion in failur...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New Zealand medical journal     Volume:  97     ISSN:  0028-8446     ISO Abbreviation:  N. Z. Med. J.     Publication Date:  1984 Feb 
Date Detail:
Created Date:  1984-05-04     Completed Date:  1984-05-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0401067     Medline TA:  N Z Med J     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  115-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acne Vulgaris / drug therapy*
Acute Disease
Cheilitis / chemically induced
Drug Evaluation
Follow-Up Studies
Time Factors
Tretinoin / administration & dosage,  adverse effects,  therapeutic use*
Reg. No./Substance:
0/Capsules; 302-79-4/Tretinoin; 4759-48-2/Isotretinoin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evidence for presynaptic inhibition of muscle spindle Ia afferents in man.
Next Document:  Effect of a single injection of cyclophosphamide on immunization therapy of metastases remaining aft...